← FDA Drug Approvals (Drugs@FDA)

RELYVRIO

NDA · New Drug Application · Sponsor: AMYLYX · Approved 2022-09-29

Drug application

FDA Application #

NDA216660

Application type

New Drug Application

Brand name

RELYVRIO

Generic name

Sodium Phenylbutyrate

Active ingredients

SODIUM PHENYLBUTYRATE; TAURURSODIOL

Dosage form

FOR SUSPENSION

Route

ORAL

Marketing status

Discontinued

Sponsor

AMYLYX

First approval

2022-09-29

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown